November 2008- Volume 4, Issue 11
In this Issue
Research & Development
Late-stage letdown
Late-stage letdown
Cell Genesys axes 75 percent of staff after cancelling VITAL-1 Phase III trials
Better late than never
Better late than never
ARCA biopharma, Nuvelo merger creates late-stage cardiovascular biotech
A partner's partnership
A partner's partnership
Ligand's acquisition of Pharmacopeia to focus on Big Pharma partnerships
Easier way to make stem cells
Easier way to make stem cells
Harvard researchers use chemicals in place of two cancer genes in reprogramming process
Cooperating for a worthy cause
Cooperating for a worthy cause
Eli Lilly, Merck and IDRI tackle global threat of TB
Genomics & Proteomics
Slashing genome prices
Slashing genome prices
Complete Genomics promises $5,000 human whole-genome sequencing by next year
Giving RNAi some lip service
Giving RNAi some lip service
RXi Pharma obtains exclusive worldwide license to technology for the oral RNAi delivery
Getting in touch with our inner germs
Getting in touch with our inner germs
NIH kicks off the Human Microbiome Project with first awards
Informatics
Gunning for genomics
Gunning for genomics
Integromics, Tibco roll out genomics data analysis solution
Making massive models
Making massive models
Biogen Idec to process inflammatory disease data using Gene Network Sciences' REFS software
Bringing down Big Pharma's fortress
Bringing down Big Pharma's fortress
SIMDAT Project ends with successful virtual outsourcing project at GSK
Early warning system
Early warning system
CSS Informatics, DrugLogic integrate safety data technologies to allow early detection of adverse trial events
In-depth in silico discovery
In-depth in silico discovery
Life Biosystems, Temis solution offers analysis of large-scale bibliographic information
Automation & Instrumentation
A perfect deal from A to Z
A perfect deal from A to Z
Advalytix to private-label ZyGEM's temperature-controlled extraction technology
Speeding up ADME
Speeding up ADME
BD Biosciences, BioTrove to provide a solution from sample prep to data analysis
Radiolabeling for ADME
Radiolabeling for ADME
PerkinElmer launches GMP radiolabeling services
Invitrogen hepatocytes pair with Qualyst’s B-Clear
Invitrogen hepatocytes pair with Qualyst’s B-Clear
In a move that should markedly enhance the market opportunities for Qualyst’s B-Clear hepatocyte research kits and contract services, the company has agreed with Invitrogen to offer hepatocyte screening services and research products through the latter’s wholly-owned subsidiary, CellzDirect.
Feature
Lighting up in vitro and in vivo work
Lighting up in vitro and in vivo work
Imaging technologies, particularly luminescent ones, are increasingly important to discovery/development
Global News
Focus on emerging markets
Focus on emerging markets
GSK snags Egyptian mature products business of Bristol-Myers Squibb for $210 million
Coming in from the cold
Coming in from the cold
Lipoxen, Cambridge Biostability work to develop improved vaccines that are stable at ambient temperatures
Pfizer to settle Bextra and Celebrex lawsuits for $894 million
Pfizer to settle Bextra and Celebrex lawsuits for $894 million
Settlement to resolve personal injury and class action lawsuits, state AG claims
Pfizer, UCB announce joint venture
Pfizer, UCB announce joint venture
New company Cyclofluidic aims to accelerate drug discovery via automating flow chemistry, flow biology
Theratechnologies, EMD Serono in HIV tesamorelin licensing deal
Theratechnologies, EMD Serono in HIV tesamorelin licensing deal
Theratechnologies Inc. and EMD Serono Inc., an affiliate of Merck KGaA, Darmstadt, Germany, announced the companies entered a collaboration and licensing agreement for the exclusive commercialization rights to tesamorelin in the United States for the treatment of excess abdominal fat in HIV patients with lipodystrophy.
Editor's Focus
Economic meltdown and where the money is
Economic meltdown and where the money is
It’s pretty hard to be the editor of a business publication and not address the recent world-wide economic meltdown. What’s to make of this mess, and what are the potential impacts on the biotech and pharmaceutical industry?
Commentary
Now what do we do? Challenges abound in life sciences for new graduates and experienced alike
Now what do we do? Challenges abound in life sciences for new graduates and experienced alike
Twenty years ago, life in Big Pharma was genteel and secure. Today, it is neither. There are always good career opportunities for the best, and the only way to be the best is to get to work and not wait for miracles.
A solid team in the life sciences
A solid team in the life sciences
Just as our editorial staff delivers the news to our readers, our sales staff delivers integrated marketing opportunities to the advertising community. DDN is very fortunate that in our fourth year, we have a veteran sales team, all of whom have deep and significant experience in life science publishing, to help our advertisers design their own customized integrated marketing programs.
